We scan new podcasts and send you the top 5 insights daily.
Triple-negative breast cancer brain metastases frequently present alongside aggressive visceral disease, making pauses for local brain therapy challenging. Emerging trial data indicate topoisomerase-1-directed ADCs penetrate the central nervous system effectively, showing prolonged activity in both parenchymal brain metastases and leptomeningeal disease.
Contrary to the expectation that large molecules like antibody-drug conjugates (ADCs) cannot penetrate the blood-brain barrier, Trastuzumab-Deruxtecan demonstrates significant CNS activity, with response rates over 40% in lung cancer patients with brain metastases. This finding is changing treatment paradigms and challenging long-held assumptions about drug delivery to the brain.
Beyond overall response rates, a critical area of excitement for new ADCs in lung cancer is their potential to treat brain metastases. Early data showing hints of intracranial efficacy is a significant point of interest, as this addresses a common and difficult-to-treat site of disease progression, offering a potential advantage over other therapies.
Unlike many traditional chemotherapies, new antibody-drug conjugates (ADCs) like IDXD are demonstrating high objective response rates (over 45%) within the brain. This intracranial efficacy is a major advance for small cell lung cancer (SCLC) patients, who frequently develop hard-to-treat brain metastases, potentially reducing reliance on immediate whole-brain radiation.
Unlike the standard chemotherapy regimen TCHP, the newer drug T-DXd can cross the blood-brain barrier. This is a crucial advantage for high-risk HER2-positive breast cancer patients, as it offers the potential to prevent brain metastases, a common and devastating site of recurrence for this cancer subtype.
The B7H3-targeted antibody-drug conjugate (ADC) ifanatumab deruxtecan shows a high intracranial response rate in SCLC, numerically even better than its systemic response rate. This suggests excellent CNS penetration, offering a promising strategy for managing brain metastases, a common and difficult challenge in SCLC.
The antibody-drug conjugate ifinatamab deruxtecan (I-O-DXd) demonstrates remarkable CNS activity. In SCLC patients with brain metastases who have not had prior radiation, the intracranial response rates are even better than the impressive systemic responses, addressing a critical unmet need for this disease.
The concept of an impermeable blood-brain barrier is less relevant once brain metastases are established. The barrier becomes highly permeable, or 'leaky,' allowing even large molecules like antibody-drug conjugates (ADCs) to penetrate the CNS. This suggests that any therapy systemically active in the periphery has potential CNS activity.
A decade ago, metastatic triple-negative breast cancer (mTNBC) had a median survival of about one year. Today, the duration of response to modern antibody-drug conjugates (ADCs) in the first-line setting can be longer than what the entire overall survival used to be, highlighting a massive therapeutic advancement.
Clinicians should be cautious not to conflate the remarkable CNS activity of trastuzumab deruxtecan (T-DXd) in HER2-positive disease with that of other ADCs, like TROP2-ADCs, in HER2-low or negative settings. Data is emerging for TROP2-ADCs, but their CNS activity is expected to be much more modest.
Unlike the intact blood-brain barrier, the blood-tumor barrier within brain metastases is permeable. This "leakiness" allows large molecules like the ADC trastuzumab deruxtecan (TDXD) to enter and deliver its payload, providing a mechanism for its high CNS efficacy.